Ribavirin is effective against drug-resistant H7N9 influenza virus infections

References

[1] Bi Y, Xie Q, Zhang S, Li Y, Xiao H, Jin T, Zheng W, Li J, Jia X, Sun L (2015) Assessment of the internal genes of influenza A (H7N9) virus contributing to high pathogenicity in mice. J Virol 89:2–13

[2] Crotty S, Maag D, Arnold JJ, Zhong WD, Lau JYN, Hong Z, Andino R, Cameron CE (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:1375–1379

[3] Gao GF (2014) Influenza and the live poultry trade. Science 344:235

[4] Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K (2013) Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368:1888–1897

[5] Gilbert BE, McLeay MT (2008) MegaRibavirin aerosol for the treatment of influenza A virus infections in mice. Antiviral Res 78:223–229

[6] Graci JD, Cameron CE (2006) Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16:37–48

[7] Hu YW, Lu SH, Song ZG, Wang W, Hao P, Li JH, Zhang XN, Yen HL, Shi BS, Li T (2013) Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273–2279

[8] Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 52:3889–3897

[9] Lam TTY, Zhou BP, Wang J, Chai YJ, Shen YY, Chen XC, Ma C, Hong WS, Chen Y, Zhang YJ (2015) Dissemination, divergence and establishment of H7N9 influenza viruses in China. Nature 522:102–U265

[10] Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, Xiang N, Chen E, Tang F, Wang D (2014) Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 370:520–532

[11] Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelthaler DM, Le MH, Keim PS, Spence RP, Went GT (2009) Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 53:4115–4126

[12] Smee DF, Bailey KW, Wong MH, Sidwell RW (2005) Activities of oseltamivir and ribavirin used alone or in combination against infections caused by mouse-adapted recent isolates of influenza A and B viruses. Antiviral Res 65:A61–A61

[13] Su S, Bi Y, Wong G, Gray GC, Gao GF, Li S (2015) Epidemiology, evolution, and recent outbreaks of avian influenza virus in china. J Virol 89:8671–8676

[14] Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F, Zhao M, Xiao H, Qin C, He J (2013) Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res 23:1347–1355

[15] Yen HL, Zhou J, Choy KT, Sia SF, Teng O, Ng IH, Fang VJ, Hu Y, Wang W, Cowling BJ (2014) The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets. J Infect Dis 210:1900–1908

RIGHTS & PERMISSIONS

2016 The Author(s) 2016. This article is published with open access at Springerlink.com and journal.hep.com.cn